

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/449,817
				Filing Date	November 26, 1999
				First Named Inventor	STEINER, Mitchell S.
				Group Art Unit	1652
				Examiner Name	KERR, K.
				Attorney Docket Number	P-2762-US1
Sheet	1	of	4		

NOV 13 2002

RECEIVED

[illegible][illegible]

Examiner Signature	<i>Kathleen Lee</i>	Date Considered	1/25/03
-----------------------	---------------------	--------------------	---------

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

+

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/449,817
		Filing Date	November 26, 1999
		First Named Inventor	STEINER, Mitchell S.
		Group Art Unit	1652
		Examiner Name	KERR, K.
Sheet	2	of	4
		Attorney Docket Number	P-2762-US1

RECEIVED
NOV 13 2002

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KIC	AI	M.WEIL, M.D. ET AL (1996) "Constitutive Expression of the Machinery for Programmed Cell Death" Journal of Cell Biology, Volume 133, Number 5, June 1996 1053-1059.	<input type="checkbox"/>
	AJ	ELISHEVA YONISH-ROUACH ET AL (1991) "Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by Interleukin-6" Letters to Nature, Vol. 352, 345 - 347.	<input type="checkbox"/>
	AK	STUART H. YUSPA ET AL. "Chemical Carcinogenesis: From Animal Models to Molecular Models in One Decade" Advances in Cancer Research Vol. 50, 25 - 70 (1989).	<input type="checkbox"/>
	AL	RENU WADHWA ET AL. (1995) "Correlation between Complementation Group for Immortality and the Cellular Distribution of Mortalin" Experimental Cell Research 216, 101-106.	<input type="checkbox"/>
	AM	BERT VOGELSTEIN M.D. ET AL. (1988) "Genetic Alterations During Colorectal-Tumor Development" The New England Journal of Medicine Volume 319, Number 9, September 4, 1988 525-532.	<input type="checkbox"/>
	AN	TEMPLEON, L ET AL. (1996) "Down-Regulation of Wild-Type p53 and Up-Regulation of PCNA by pXP2 gene are Associated with the Partial Correction of NER in the XP-A transfectant." Proc. Of the American Association for Clinical Res. 37, 499, 1996.	<input type="checkbox"/>
	AO	MITCHELL S. STEINER ET AL. (1995) "Molecular Insights into Altered Cell Cycle Regulation and Genitourinary Malignancy" Urol Oncol 1: 3-17.	<input type="checkbox"/>
	AP	MITCHELL S. STEINER ET AL. (1992) "Transforming Growth Factor-β1 Overproduction in Prostate Cancer: Effects on Growth In Vivo and In Vitro" The Endocrine Society 1992 Molecular Endocrinology 6(1):15-25.	<input type="checkbox"/>
	AQ	EDWIN SILVERBER, BS. (1987) "Statistical and Epidemiologic Data on Urologic Cancer" Department of Epidemiology and Statistics, Department of Research, American Cancer Society, New York Feb 6, 1987. Cancer 1: 60 (3 suppl): 692-717.	<input type="checkbox"/>
	AR	PETER G. SHIELDS, MD ET AL (1991) "Molecular Epidemiology and the Genetics of Environmental Cancer" JAMA 1991; 266:681-687.	<input type="checkbox"/>
	AS	CHARLES J. SHERR (1993) "Mammalian G, Cyclins" Cell, Vol. 73, 1059-1065, June 18, 1993	<input type="checkbox"/>



corrections K. Kerr 1/25/03

Examiner Signature	<i>Kathleen Kerr</i>	Date Considered	1/25/03
--------------------	----------------------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

+

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/449,817
		Filing Date	November 26, 1999
		First Named Inventor	STEINER, Mitchell S.
		Group Art Unit	1652
		Examiner Name	KERR, K.
Sheet	3	of	4
		Attorney Docket Number	P-2762-US1

TECH CENTER 1500/2500-

NOV 13 2002

RECEIVED

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
KK	AT	AUGUSTINUS RINALDY ET AL (1990) "Increased UV Resistance in Xeroderma Pigmentosum Group A Cells after Transformation with a Human Genomic DNA Clone" Proc. Natl. Acad. Sci. USA Vol. 87 pp. 6818-6822, September 1990	<input type="checkbox"/>
KK	AU	AUGUSTINUS RINALDY ET AL. (1988) "Laboratory Methods, Gene Cloning Using cDNA Libraries in a Differential Competition Hybridization Strategy; Application to Cloning XP-A Related Genes" DNA Volume 7, Number 8, 1988, Mary Ann Liebert, Inc., Publishers pp. 563-570.	<input type="checkbox"/>
KK	AV	DAN MICHALOVITZ ET AL. (1990) "Conditional Inhibition of Transformation and of Cell Proliferation by a Temperature-Sensitive Mutant of p53" Department of Chemical Immunology, Cell, Vol 62, 671-680, August 24, 1990	<input type="checkbox"/>
KK	AW	KILLIAN MELLON ET AL. (1992) "p53, c-erbB-2 and the Epidermal Growth Factor Receptor in the Benign and Malignant Prostate" The Journal of Urology Vol. 147, 496-499 February 1992.	<input type="checkbox"/>
	AX	TIMOTHY J. MCDONNELL ET AL (1992) "Expression of the Protooncogene bcl-2 in the Prostate and Its Association with Emergence of Androgen-independent Prostate Cancer" Cancer Research 52, 6940-6944, December 15, 1992	<input type="checkbox"/>
	AY	DAWN L. MCLELLAN BSC ET AL (1995) "Hereditary Aspects of Prostate Cancer" Can. Med. Assoc. J, Oct 4, 1995; 153 (7): 895-900.	<input type="checkbox"/>
	AZ	EDWIN H. MCCONKEY "The Fractionation of RNA's by Sucrose Gradient Centrifugation" Isolation and Fractionation of Nucleic Acids Methods in Enzymology (83) 620-634 (1982).	<input type="checkbox"/>
	BA	GIORGIO MANGIAROTTI ET AL (1981) "Selection and Analysis of Cloned Developmentally-Regulated Dictyostellum Discoideum Genes by Hybridization-Competition" Nucleic Acid Research Volume 9 Number 4, 1981 947-963.	<input type="checkbox"/>
	BB	ROBERT B. AMSON, ET AL (1996) "Isolation of 10 differentially expressed cDNAs in p53-Induced Apoptosis: Activation of the Vertebrate Homologue of the Drosophila Seven in Absentia Gene" Proc. Natl. Acad. Sci. USA 93, 3953-3957.	<input type="checkbox"/>
KK	BC	TERUO IWASAKI ET AL (1995) "Cell-Cycle-Dependent Invasion In Vitro by Rat Ascites Hepatoma Cells" Publication of the International Union Against Cancer, Int. J. Cancer: 63, 282-287 (1995)	<input type="checkbox"/>
KK	BD	JOHN T. ISAACS, ET AL. (1982) "Genetic Instability Coupled to Clonal Selection as a Mechanism for Tumor Progression in the Dunning R-3327 Rat Prostatic Adenocarcinoma System" Cancer Research 42, 2353-2361, June 1982	<input type="checkbox"/>

Examiner Signature	<i>Kathleen Ka</i>	Date Considered	1/25/03
--------------------	--------------------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

corrections K. Kerr 1/25/03

OIPB
NOV 1 2002
PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box

+

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/449,817		
		Filing Date	November 26, 1999		
		First Named Inventor	STEINER, Mitchell S.		
		Group Art Unit	1652		
		Examiner Name	KERR, K.		
Sheet	4	of	4	Attorney Docket Number	P-2762-US1

TECHCENTER 600/2300

NOV 13 2002

RECEIVED

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KK	BE	JOHN T. ISAACS, ET AL (1986) "Establishment and Characterization of Seven Dunning Rat Prostatic Cancer Cell Lines and Their Use in Developing Methods for Predicting Metastatic Abilities of Prostatic Cancers" The Prostate 9: 261-281 (1986) .	<input type="checkbox"/>
KK	BF	WILLIAM B. ISAACS, ET AL (1991) "Wild-Type p53 Suppresses Growth of human Prostate Cancer Cells Containing Mutant p53 Alleles" Cancer Research 51: 4716-4720, September 4, 1991	<input type="checkbox"/>
KK	BG	MAKOTO INABA, ET AL (1996) "Reduced Activity of Anabolizing Enzymes In 5-Fluorouracil-resistant Human Stomach Cancer Cells" JPN. J. Cancer Res. 87, 212-220, February 1996	<input type="checkbox"/>
KK	BH	HOWARD K. GERSHENFELD, ET AL (1986) "Cloning of a cDNA for a T Cell-Specific Serine Protease from a Cytotoxic T Lymphocyte" Science, Volume 232, 46 May 1986 854-858.	<input type="checkbox"/>
KK	BI	R.E.K. FOURNIER, ET AL (1977) "Microcell-Mediated Transfer of Murine Chromosomes Into Mouse, Chinese Hamster, and Human Somatic Cells" Proc. Natl. Acad. Sci. USA, Vol. 74, No. 1. pp. 319-323, January 1977 Genetics	<input type="checkbox"/>
KK	BJ	WAFIK S EL-DEIRY, ET AL (1994) "WAF1/CIP1 Is Induced in p53-mediated G ₁ Arrest and Apoptosis" Cancer Research 54, 1169-1174, March 4, 1994	<input type="checkbox"/>
KK	BK	PETER J. EFFERT, ET AL (1992) "Alterations of the P53 Gene are Associated with the Progression of a Human Prostate Carcinoma" The Journal of Urology Vol. 147, 789-793, March 1992- et al.	<input type="checkbox"/>
KK	BL	BOB S. CARTER, (1992) "Mendelian Inheritance of Familial Prostate Cancer "Proc. Natl. Acad. Sci. USA Vol. 89. pp. 3367-3371, April 1992-	<input type="checkbox"/>
KK	BM	H. BALLENTINE CARTER, ET AL (1990) "Clinical Evidence for and Implications of the Multistep Development of Prostate Cancer" The Journal of Urology Vol. 143, April 1990- 742-746.	<input type="checkbox"/>
KK	BN	SHUBHA ANAND, ET AL (1995) "Induction of Apoptosis in Chronic Myelogenous Leukemia Lymphocytes by Hydroxyurea and Adriamycin" Cancer Letters 88 (1995) 101-105,	<input type="checkbox"/>
			<input type="checkbox"/>

NOV 12 2002
PATENT & TRADEMARK OFFICE

connections K. Kerr 1/25/03

Examiner Signature	<i>Kathleen Kerr</i>	Date Considered	1/25/03
--------------------	----------------------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.